Elkord E
Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
Chem Immunol Allergy. 2008;94:150-157. doi: 10.1159/000154999.
Natural CD4+CD25+FoxP3+ regulatory T cells (Treg) actively suppress physiological and pathological responses, therefore playing a critical role in controlling peripheral tolerance to self antigens and maintaining immune homeostasis. In normal individuals, natural Treg and interleukin- 10-secreting Treg are able to suppress Th2 responses to allergens, whereas lower levels of Treg or defect in their functionality have been described as potential mechanisms for inducing allergic diseases. In animal models, adoptive transfer of CD4+CD25+Treg has been shown as a promising strategy for preventing or treating allergic disorders. Recent studies show that induction of Treg activity is associated with suppression of allergic responses in allergic patients treated with specific immunotherapy. Herein, I review the potential of Treg as exciting targets for developing new immunotherapeutic strategies for treating allergic diseases.
天然CD4+CD25+FoxP3+调节性T细胞（Treg）可积极抑制生理和病理反应，因此在控制对外源性抗原的外周耐受及维持免疫稳态方面发挥着关键作用。在正常个体中，天然Treg和分泌白细胞介素-10的Treg能够抑制Th2对过敏原的反应，而Treg水平较低或其功能缺陷被认为是诱发过敏性疾病的潜在机制。在动物模型中，过继转移CD4+CD25+Treg已被证明是预防或治疗过敏性疾病的一种有前景的策略。最近的研究表明，在接受特异性免疫治疗的过敏性患者中，Treg活性的诱导与过敏反应的抑制相关。在此，我综述了Treg作为开发治疗过敏性疾病新免疫治疗策略的令人兴奋的靶点的潜力。
